EA201490766A1 - Комбинированная терапия рака яичников - Google Patents

Комбинированная терапия рака яичников

Info

Publication number
EA201490766A1
EA201490766A1 EA201490766A EA201490766A EA201490766A1 EA 201490766 A1 EA201490766 A1 EA 201490766A1 EA 201490766 A EA201490766 A EA 201490766A EA 201490766 A EA201490766 A EA 201490766A EA 201490766 A1 EA201490766 A1 EA 201490766A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ovarian cancer
combined therapy
ylamine
dimethylpropyl
gemcitabine
Prior art date
Application number
EA201490766A
Other languages
English (en)
Other versions
EA026297B1 (ru
Inventor
Эдвард Майкл Чань
Сьюзан Элизабет Пратт
Луис Франк Станкато
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201490766A1 publication Critical patent/EA201490766A1/ru
Publication of EA026297B1 publication Critical patent/EA026297B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

В изобретении предложен способ лечения рака яичников у нуждающегося в таком лечении млекопитающего, включающий введение эффективного количества комбинации гемцитабина, цисплатина или карбоплатина, и 5-[2-трет-бутил-5-(4-фторфенил)-1H-имидазол-4-ил]-3-(2,2-диметилпропил)-3H-имидазо[4,5-b]пиридин-2-иламина.
EA201490766A 2011-11-11 2012-10-31 Комбинированная терапия рака яичников EA026297B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161558582P 2011-11-11 2011-11-11
PCT/US2012/062634 WO2013070460A1 (en) 2011-11-11 2012-10-31 Combination therapy for ovarian cancer

Publications (2)

Publication Number Publication Date
EA201490766A1 true EA201490766A1 (ru) 2014-08-29
EA026297B1 EA026297B1 (ru) 2017-03-31

Family

ID=47146746

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490766A EA026297B1 (ru) 2011-11-11 2012-10-31 Комбинированная терапия рака яичников

Country Status (30)

Country Link
US (1) US9844529B2 (ru)
EP (1) EP2780011B1 (ru)
JP (1) JP6055481B2 (ru)
KR (1) KR101647569B1 (ru)
CN (1) CN103917233B (ru)
AP (1) AP3881A (ru)
AU (1) AU2012336154B2 (ru)
BR (1) BR112014011197A2 (ru)
CA (1) CA2850559C (ru)
CR (1) CR20140211A (ru)
CY (1) CY1120315T1 (ru)
DK (1) DK2780011T3 (ru)
DO (1) DOP2014000100A (ru)
EA (1) EA026297B1 (ru)
ES (1) ES2671730T3 (ru)
HR (1) HRP20180875T1 (ru)
HU (1) HUE037928T2 (ru)
IL (1) IL232479A0 (ru)
LT (1) LT2780011T (ru)
ME (1) ME03035B (ru)
MX (1) MX2014005698A (ru)
MY (1) MY168927A (ru)
PL (1) PL2780011T3 (ru)
PT (1) PT2780011T (ru)
RS (1) RS57256B1 (ru)
SG (1) SG11201401795XA (ru)
SI (1) SI2780011T1 (ru)
TN (1) TN2014000150A1 (ru)
WO (1) WO2013070460A1 (ru)
ZA (1) ZA201403159B (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015154064A2 (en) 2014-04-04 2015-10-08 Del Mar Pharmaceuticals Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer
HRP20221196T1 (hr) 2017-10-05 2022-12-09 Fulcrum Therapeutics, Inc. Inhibitori p38 kinaze smanjuju ekspresiju dux4 i nizvodnih gena u cilju liječenja fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9916735A (pt) * 1998-12-31 2001-09-25 Sugen Inc Compostos de 3-heteroarilidenil-2-indolinona para a modulação da atividade das cinases protéicas e para uso na quimioterapia do cancêr
TWI332003B (en) * 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors

Also Published As

Publication number Publication date
ZA201403159B (en) 2017-11-29
PT2780011T (pt) 2018-05-14
WO2013070460A1 (en) 2013-05-16
CY1120315T1 (el) 2019-07-10
EP2780011B1 (en) 2018-04-11
DOP2014000100A (es) 2014-06-30
BR112014011197A2 (pt) 2017-04-25
AU2012336154A1 (en) 2014-04-17
CR20140211A (es) 2014-06-20
MX2014005698A (es) 2014-08-21
CN103917233B (zh) 2018-11-16
JP2014533270A (ja) 2014-12-11
JP6055481B2 (ja) 2016-12-27
HRP20180875T1 (hr) 2018-07-13
CA2850559C (en) 2016-11-29
AP3881A (en) 2016-10-31
EP2780011A1 (en) 2014-09-24
TN2014000150A1 (en) 2015-09-30
CN103917233A (zh) 2014-07-09
ES2671730T3 (es) 2018-06-08
NZ623622A (en) 2015-07-31
KR20140083010A (ko) 2014-07-03
IL232479A0 (en) 2014-06-30
DK2780011T3 (en) 2018-05-28
CA2850559A1 (en) 2013-05-16
HUE037928T2 (hu) 2018-09-28
LT2780011T (lt) 2018-05-10
PL2780011T3 (pl) 2018-08-31
EA026297B1 (ru) 2017-03-31
MY168927A (en) 2019-01-08
AP2014007631A0 (en) 2014-05-31
RS57256B1 (sr) 2018-08-31
SG11201401795XA (en) 2014-09-26
US9844529B2 (en) 2017-12-19
ME03035B (me) 2018-10-20
KR101647569B1 (ko) 2016-08-10
SI2780011T1 (en) 2018-07-31
AU2012336154B2 (en) 2017-01-12
US20140302174A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
MX2017016491A (es) Metodos para tratar malignidad hematologica usando terapia combinada de nanoparticulas de inhibidor de objetivo mamifero de la rapamicina (mtor).
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
MY162903A (en) Methods of treatment of pancreatic cancer
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
BR112015016681A2 (pt) métodos de tratamento de câncer pancreático
EA202092187A1 (ru) Способы лечения эпителиоидно-клеточных опухолей
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
BR112015007184A2 (pt) combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer
MX2015008888A (es) Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
BR112014028017A2 (pt) composto, composição farmacêutica, método para tratar um distúrbio, método para reduzir a quantidade il-17 em um indivíduo e método para inibir a atividade de ror
MX2017002852A (es) Activacion de linfocitos que infiltran la medula en condiciones hipoxicas alternando con normoxicas.
BR112017003571A2 (pt) terapia combinada
EA201891514A1 (ru) Комбинированная терапия ингибитором бромодомена и экстратерминального белка
CY1120877T1 (el) Συνθεσεις και μεθοδοι για την αντιμετωπιση της κοιλιοκακης
EA201591424A1 (ru) Способы лечения дефицита железа растворимым пирофосфатом железа
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.
CY1120315T1 (el) Συνδυαστικη θεραπεια για καρκινο των ωοθηκων
CY1117438T1 (el) Μεθοδος για την προληψη και την θεραπευτικη αντιμετωπιση της σηψης
MX2019004804A (es) Tratamiento para el prurigo nodula.
EA201491581A1 (ru) Везикулярные композиции
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU